beta-Amyloid Aggregation Inhibitors for the Treatment of Alzheimer Disease Dream or Reality?

Author(s): Patrice Talaga

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 1 , Issue 2 , 2001

Become EABM
Become Reviewer


Amyloid (A beta) deposition remains a hallmark in the pathology of Alzheimer disease (AD). Important drug discovery efforts dedicated to the inhibition of the polymerization process leading to amyloid neurotoxicity are pursued by academic groups and the pharmaceutical industry as a potential preventive treatment for AD. The aim of this review is to up-date current knowledge on the amyloid aggregation process and the various available peptidic and non-peptidic A beta aggregation inhibitors.

Keywords: Aggregation Inhibitors, Alzheimers Disease, Anti-inflammatory agents, Antioxidants, Neurotrophic, Ab Aggregation Inhibition, AMYLOID AGGREGATION INHIBITORS, Thyrotrophin releasing hormone (TRH), Melatonin, Hexadecyl-N-methylpiperidinium (HMP) bromide

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2001
Page: [175 - 186]
Pages: 12
DOI: 10.2174/1389557013407098
Price: $65

Article Metrics

PDF: 3